Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other financing activities: 2018-2024

  • Crinetics Pharmaceuticals' Other financing activities fell 3617.72% to -$15.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$11.5 million, marking a year-over-year change of. This contributed to the annual value of $26,000 for FY2023, which is N/A change from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Other financing activities stood at -$15.9 million for Q4 2024, which was down 468.76% from $4.3 million recorded in Q1 2024.
  • Crinetics Pharmaceuticals' Other financing activities' 5-year high stood at $4.3 million during Q1 2024, with a 5-year trough of -$15.9 million in Q4 2024.
  • Moreover, its 2-year median value for Other financing activities was -$429,000 (2023), whereas its average is -$4.0 million.
  • Data for Crinetics Pharmaceuticals' Other financing activities shows a maximum YoY slumped of 3,617.72% (in 2024) over the last 5 years.
  • Over the past 2 years, Crinetics Pharmaceuticals' Other financing activities (Quarterly) stood at -$429,000 in 2023, then plummeted by 3,617.72% to -$15.9 million in 2024.
  • Its last three reported values are -$15.9 million in Q4 2024, $4.3 million for Q1 2024, and -$429,000 during Q4 2023.